Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E SANBORN

Showing results (151-160 of 173) with videos related to

Pageof 18
Sort By:
Future Oncology (London, England)|March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 TrialPaolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.
Clinical Lung Cancer|March 10, 2026
Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA StudyAnna Minchom, Byoung Chul Cho, Natasha B Leighl, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung CancerLeora Horn, Jennifer G Whisenant, Heather Wakelee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung CancerMichael R Shafique, Terrence L Fisher, Elizabeth E Evans, et al.
Journal of Hematology & Oncology|June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapiesQuchang Ouyang, Jordi Rodon, Yan Liang, et al.
Journal for Immunotherapy of Cancer|August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumorsRachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief ReportGregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.
Nature Medicine|September 14, 2023
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trialByoung Chul Cho, Dong-Wan Kim, Alexander I Spira, et al.
Meteoritics & Planetary Science|January 29, 2021
The fall, recovery, classification, and initial characterization of the Hamburg, Michigan H4 chondritePhilipp R Heck, Jennika Greer, Joseph S Boesenberg, et al.
Pageof 18

Showing results (151-160 of 173) with videos related to

Sort By:
Pageof 18
Future Oncology (London, England)|March 30, 2026
A plain language summary of the updated results from the PHAROS study: the combination of encorafenib plus binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancerMelissa L Johnson, Egbert F Smit, Enriqueta Felip, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2023
Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 TrialPaolo Antonio Ascierto, Evan J Lipson, Reinhard Dummer, et al.
Clinical Lung Cancer|March 10, 2026
Subcutaneous Delivery of Amivantamab in Patients With Advanced Solid Malignancies: The Phase Ib PALOMA StudyAnna Minchom, Byoung Chul Cho, Natasha B Leighl, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 26, 2019
Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung CancerLeora Horn, Jennifer G Whisenant, Heather Wakelee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung CancerMichael R Shafique, Terrence L Fisher, Elizabeth E Evans, et al.
Journal of Hematology & Oncology|June 6, 2025
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapiesQuchang Ouyang, Jordi Rodon, Yan Liang, et al.
Journal for Immunotherapy of Cancer|August 8, 2022
Safety, tolerability and efficacy of agonist anti-CD27 antibody (varlilumab) administered in combination with anti-PD-1 (nivolumab) in advanced solid tumorsRachel E Sanborn, Michael J Pishvaian, Margaret K Callahan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 6, 2025
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC-A Brief ReportGregory J Riely, Myung-Ju Ahn, Jeffrey M Clarke, et al.
Nature Medicine|September 14, 2023
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trialByoung Chul Cho, Dong-Wan Kim, Alexander I Spira, et al.
Meteoritics & Planetary Science|January 29, 2021
The fall, recovery, classification, and initial characterization of the Hamburg, Michigan H4 chondritePhilipp R Heck, Jennika Greer, Joseph S Boesenberg, et al.
Pageof 18